DN 022
Alternative Names: DN-022Latest Information Update: 15 Sep 2021
At a glance
- Originator Shanghai De Novo Pharmatech
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 02 Sep 2021 DN 022 is available for licensing as of 02 Sep 2021. http://www.denovo-sh.com/En/technology.aspx?BaseInfoCateID=48&CateID=48
- 02 Sep 2021 Early research in Solid tumours in China (unspecified route) before September 2021 (Shanghai De Novo Pharmatech pipeline, September 2021)